Literature DB >> 3754863

Structure and expression of a cloned cDNA for human (2'-5')oligoadenylate synthetase.

S Shiojiri, R Fukunaga, Y Ichii, Y Sokawa.   

Abstract

17S poly(A)+RNA, which hybridized to an oligonucleotide complementary to a part of the partial cDNA (E1cDNA) (Merlin et al. (1983) Proc. Natl. Acad. Sci. U.S. 80, 4904) for 2-5A synthetase, was isolated from interferon-treated human KB cells and used for cDNA cloning. Several overlapping cDNAs were cloned by using the oligonucleotide as a probe. Two of them were joined at their overlapping region, resulting in a cDNA (22-1 cDNA) of 1.4 kb containing a long open reading frame. When the cDNA was expressed in COS-7 cells with an eukaryotic promoter, active 2-5A synthetase was produced and localized mainly in the cytoplasm. The 5'-proximal ATG in 22-1 cDNA is followed immediately by another ATG. This second ATG was assumed to work as the initiator codon. If so, this enzyme comprises 363 amino acids.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3754863     DOI: 10.1093/oxfordjournals.jbchem.a135615

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  9 in total

1.  Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: induction of interferon-responsive RNAs.

Authors:  H Zhu; J P Cong; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

2.  Mouse 2-5A synthetase cDNA: nucleotide sequence and comparison to human 2-5A synthetase.

Authors:  Y Ichii; R Fukunaga; S Shiojiri; Y Sokawa
Journal:  Nucleic Acids Res       Date:  1986-12-22       Impact factor: 16.971

3.  Interferon-induced binding of nuclear factors to promoter elements of the 2-5A synthetase gene.

Authors:  M N Rutherford; G E Hannigan; B R Williams
Journal:  EMBO J       Date:  1988-03       Impact factor: 11.598

Review 4.  Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance.

Authors:  Young-Jun Park; Yeonseok Chung; Da-Sol Kuen
Journal:  Exp Mol Med       Date:  2018-08-22       Impact factor: 8.718

5.  Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.

Authors:  Meenu Sharma; Hiep Khong; Faisal Fa'ak; Salah-Eddine Bentebibel; Louise M E Janssen; Brent C Chesson; Caitlin A Creasy; Marie-Andrée Forget; Laura Maria S Kahn; Barbara Pazdrak; Binisha Karki; Yared Hailemichael; Manisha Singh; Christina Vianden; Srinivas Vennam; Uddalak Bharadwaj; David J Tweardy; Cara Haymaker; Chantale Bernatchez; Shixia Huang; Kimal Rajapakshe; Cristian Coarfa; Michael E Hurwitz; Mario Sznol; Patrick Hwu; Ute Hoch; Murali Addepalli; Deborah H Charych; Jonathan Zalevsky; Adi Diab; Willem W Overwijk
Journal:  Nat Commun       Date:  2020-01-31       Impact factor: 14.919

6.  Critical role of a common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-inducible genes.

Authors:  L F Reis; H Harada; J D Wolchok; T Taniguchi; J Vilcek
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

7.  Regulation of interferon responses in medulloblastoma cells by interferon regulatory factor-1 and -2.

Authors:  K C Park; K Shimizu; T Hayakawa; N Tanaka
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

Review 8.  The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.

Authors:  M R Player; P F Torrence
Journal:  Pharmacol Ther       Date:  1998-05       Impact factor: 12.310

Review 9.  The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.

Authors:  Alexandra Schnell; Lloyd Bod; Asaf Madi; Vijay K Kuchroo
Journal:  Cell Res       Date:  2020-01-23       Impact factor: 25.617

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.